Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation.
Total raised: $13.48M
Founded date: 2019
Investors 2
| Date | Name | Website |
| - | Idinvest P... | idinvest.c... |
| - | Kurma Part... | kurmapartn... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.07.2022 | - | $6.55M | - |
| 11.09.2019 | Series A | $6.93M | - |
Mentions in press and media 5
| Date | Title | Description |
| 10.11.2023 | Which Parisian Biotech Startups are Pioneering Industry Innovations in 2023? | Paris, the global hub for art, fashion, gastronomy, and culture is now extensively recognized for its astonishing progress in the Biotechnology industry. A new era of innovation and entrepreneurship is Growing in Ile-de-France, leading to a... |
| 19.09.2023 | Which Biotech Startups are Transforming Ile-de-France’s Industry Landscape in 2023? | Ile-de-France, a densely populated region encompassing the French capital, Paris, is also emerging as a hotbed of cutting-edge biotechnology startups. With French companies developing innovative solutions across fields like life sciences, g... |
| 04.07.2022 | Ermium Therapeutics Raises Further €6M in Funding; Brings Total to €12.3M | Ermium Therapeutics, a Paris, France-based biotech company, raised €6.3M in funding, bringing total funding to date to €12.3m. The round was led by Kurma Partners and Fountain Healthcare Partners. The company intends to use them funds to re... |
| 30.06.2022 | Ermium Therapeutics extends its initial €6.3 M funding to €12.3 M to further advance breakthrough auto-immune disease therapeutics | Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-immune diseases, announced today the extension of its initial funding of €6.3 M to €12.3 M with Kurma Partners and Fountain Healthcare Partner... |
| - | Ermium Therapeutics Strengthen Its Leadership Team With the Recent Appointment of Dr Annegret Van Der Aa as CSO/CDO | PARIS--(BUSINESS WIRE)--Mar 9, 2021-- Ermium Therapeutics SAS, a research-stage biotechnology company developing innovative therapies for auto-immune diseases is announcing today the expansion of the Company executive management team with t... |